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Elevated blood pressure (BP) is an established prognostic factor after acute stroke,1,2 although evidence as to the 
effect of BP lowering on outcome is partly conflicting, with 
some large studies reporting near positive effects on func-
tional outcome3 but others, including the recent Efficacy of 
Nitric Oxide in Stroke (ENOS) trial,4 reporting neutral5 or 
near negative results.6 BP variability (BPV) may be impor-
tant in the acute stroke period. Within-individual systolic BPV 
(SBPV) is a risk factor for stroke and cardiovascular events, 
independent of mean absolute BP level.7,8 Furthermore, there 
are highly consistent drug class effects on interindividual and 
intraindividual variability in BP.9,10 The variable efficacies 
of different antihypertensive agents on stroke risk reduction 
cannot be explained purely by effects on mean BP reduction 
alone, and thus, BPV may provide a potentially modifiable 
therapeutic target.8 Available evidence on the effect of BPV 
on outcome after acute stroke is scarce, and data are lacking 
as to the natural history of BPV in acute stroke, its defini-
tion, and the most appropriate measurement technique. There 
are currently no available systematic reviews on BPV in the 
acute-stroke setting.
This systematic review addresses the above points by 
investigating the existing evidence of the effect of SBPV on 
outcome after stroke, including mortality, functional depen-
dency, and adverse neuroimaging outcomes. In addition, we 
consider the BP measurement techniques used, including 
casual cuff measurements, and beat-to-beat and 24-hour or 
ambulatory monitoring. Statistical techniques to derive BPV 
are also considered. This review is reported according to the 
Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines.11
Methods
Search Strategy and Selection Criteria
A prespecified study protocol was followed. A literature search in 
the bibliographic databases MEDLINE (1948 to present), Web 
of Science (1970 to present), EMBASE (1980 to present), AMED 
(1985 to present), The Cochrane Library, Cochrane Stroke Group 
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Trials Register, Cochrane Central Register of Controlled Trials, 
SCOPUS (1966 to present), and Index to UK theses was performed 
independently by 2 researchers. Databases of ongoing trials were 
also searched: ClinicalTrials.gov, Current Controlled Trials Stroke 
Trials Register, and WHO International Clinical Trials Registry. 
Combinations of search terms used were “Stroke” or “cerebr* vas-
cular disease” or “cerebr* ischaemia” or “intracerebr* haemorrhage” 
or “cerebr* haemorrhage” or “brain isch*” or “brain haemorrhage” 
and “blood pressure” or “BP” or “hypertension” or “blood pressure 
variability” or “BPV” and “outcome*” or “prognos*” or “predict*” 
or “mortality” or “death” or “dependenc*” or “disability” or “neu-
rological deterioration” or “functional depenc*”. MeSH terms and 
groupings were adapted as appropriate, for each database. The search 
was limited to studies involving humans and adults. The references 
of selected studies and relevant reviews were hand searched for ad-
ditional relevant articles.
Randomized controlled trials, controlled trials, cohort studies, 
and observational studies that assessed the effect of BPV on outcome 
after acute ischemic stroke or primary intracerebral hemorrhage 
(ICH) were included. Eligibility was assessed by reading abstracts 
and, if necessary, whole articles. Studies in which BPV was not re-
ported within the first 7 days of stroke onset were excluded, as were 
those which did not report clinical outcome measures of interest, 
namely death, disability, dependency, neurological deterioration, 
recurrent vascular events, or radiological mechanisms for poor out-
comes (hemorrhagic transformation, cerebral edema, and hematoma 
expansion). Disability was measured as the modified Rankin Scale 
(mRS). Neurological deterioration was defined as worsening on a 
stroke neurological impairment scale (National Institute of Stroke 
Scale Score) or equivalent. Studies that gave insufficient detail on 
BP measurements or BPV calculations were excluded. Full study 
inclusion and exclusion criteria can be found in the study protocol 
(online-only Data Supplement). Study quality and risk of bias were 
assessed using a checklist adapted from authors, editors, and reviews 
of meta-analyses of observational studies12 (Table I in the online-only 
Data Supplement).
Statistical Analysis
Given the potential heterogeneity of included studies, we exercised 
caution in deciding whether a meta-analysis was appropriate. We 
used consensus opinion (L.M., T.G.R., and P.M.R.) to determine 
whether meta-analysis was appropriate for each of our outcomes of 
interest, and if so, which studies were suitable for inclusion, based 
on common methodology, BPV parameters and definitions, defini-
tions of outcome, and the reporting of results. In the event of un-
certainty surrounding study inclusion, further statistical advice and 
opinion was sought from statisticians at the University of Oxford, 
United Kingdom. Where meta-analysis was not deemed appropriate, 
we describe results in a descriptive manner.
Our primary analyses were based on studies reporting the effect 
of BPV on poor functional outcome, defined as death or major dis-
ability (mRS or equivalent), and secondary analyses were based on 
studies reporting the effect on predefined radiological outcomes and 
the effect on early neurological outcome. Studies were included only 
if authors reported odds ratios (OR) and 95% confidence intervals 
(CIs) for the effect of a defined increment (eg, per 10-mm Hg in-
crease or 1-SD increase) in either SD of SBP (SD SBP) or coef-
ficient of variation of SBP (CV SBP), on outcome. Studies using 
BPV parameters other than SD or CV were not included as such 
indices (eg, successive variation [SV] and average real variability 
are not directly comparable with SD or CV, and equivalent values 
cannot be accurately derived. Where ORs were adjusted for poten-
tially confounding factors in multivariable analyses, the adjusted 
OR and 95% CI were used in the meta-analysis. In-house software 
(a previously validated macro within Microsoft EXCEL 2003) was 
used to calculate pooled ORs, 95% CIs, P values for significance, 
and Cochran Q statistic for heterogeneity, assuming a fixed effects 
model (Mantel–Haenszel–Peto method) with effect sizes weighted 
according to the reciprocal of their variance. Statistical significance 
was set at P<0.05.
Results
Eighteen articles of 1359 originally identified citations were 
included (Figure I in the online-only Data Supplement). No 
randomized controlled trials were identified. Seven stud-
ies were of a prospective observational nature,13–19 5 were 
observational analyses of prospective stroke registry data,20–24  
and 6 were observational analyses of previous randomized 
controlled trial data.25–30 Study sample size varied from 71 
to 2645 participants. Eight studies were deemed suitable 
to include in the meta-analysis for effect of BPV on func-
tional outcome.14,15,17,18,20,22,26,27 The remaining 10 studies 
were excluded from this analysis because of heterogeneity 
in methodology and reporting (Table II in the online-only 
Data Supplement).13,16,19,21,23–25,28–30 One further study was later 
excluded from the meta-analysis on the basis that it was a 
small study with an extreme effect,15 leaving 7 studies in the 
final analysis. We provide results for the meta-analysis includ-
ing and excluding this extreme outlier.
The median checklist quality score was 12 (range, 7–15), 
highlighting the heterogeneity in study methodology report-
ing and incomplete reporting of key criteria in many studies 
(Table III in the online-only Data Supplement). Fifteen studies 
included patients with acute ischemic stroke only,13–18,20–25,28–30 
1 study included both patients with ischemic stroke and ICH,27 
and 2 included only those with primary ICH.19,26 Study charac-
teristics are shown in the Table.
Fifteen studies measured BP using casual BP cuffs13,15,18–30; 
1 study used 24-hour ambulatory BP monitors17; and 2 used 
beat-to-beat BP monitors.14,16 Thirteen studies enrolled 
patients and started BP measurements within 24 hours of 
stroke onset,13,15,17–21,23,24,26,28–30 10 of these within the first 6 
hours.15,18–21,23,26,28–30 Of the remaining studies, 2 recruited 
patients within 48 hours,25,27 1 within 72 hours,14 1 at 72 
hours,22 and the remaining study within the first 7 days.16 
The duration of time over which BPV was calculated varied 
from 10 minutes to ≈137 hours. A variety of parameters were 
used to define BPV (outlined in Figure II and Table IV in the 
online-only Data Supplement). The Table shows BP measure-
ment techniques, timings, and parameters used.
Fifteen studies reported functional status (death or dis-
ability) as an outcome measure; all used dichotomized mRS 
scores. Thirteen studies reported functional outcome at 90 
days,13,15–22,26,28–30 1 at 30 days,14 and 1 at 14 days.27 Six stud-
ies reported neurological improvement or deterioration as an 
outcome measure.15,16,18,19,25,28 Eight studies reported outcome 
data relating to neuroimaging findings: 7 studies used hemor-
rhage or hematoma expansion on repeat imaging within 14 
days of onset as an outcome measure (with heterogeneity in 
definitions and timing of scans).18–21,23,26,29 Further details can 
be found in Table V in the online-only Data Supplement.
Thirteen studies used logistic regression models to inves-
tigate associations between BPV parameters and outcome, 
reporting ORs, and 95% CIs.14,15,20–30 Three studies used other 
forms of multivariable analyses,17–19 and 2 simply compared 
BPV parameters between good and poor outcome groups.13,16 
Although most studies adjusted analyses for baseline prognos-
tic variables, only 7 studies adjusted for baseline BP level or 
mean BP.18,19,22,23,26–28
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To assess the effect of BPV on functional outcome, we 
report the results of our meta-analyses and provide a descrip-
tive analysis of our findings. Heterogeneity in study method-
ology precluded a formal meta-analysis for the effect of BPV 
on radiological outcomes or on short-term neurological out-
come, although several nonstatistically significant trends are 
apparent, as discussed below. Table VI in the online-only Data 
Supplement summarizes the effect of BPV on outcome in all 
studies.
Seven studies were deemed eligible for inclusion in meta-
analyses to assess the pooled effect of SBPV on functional 
outcome.14,17,18,20,22,26,27 All used dichotomized mRS scores 
to define poor versus favorable outcomes. Where studies 
reported ORs for the effect on favorable mRS scores,18,20 ORs 
were inverted, to provide OR for poor outcome. All studies 
used either SD or CV SBP as their key variability parameter. 
Three studies quoted ORs and 95% CIs per 10-mm Hg incre-
ment in BPV parameter,17,18,20 3 reported ORs and 95% CIs for 
each 1-SD increment in BPV parameter,22,26,27 and 1 reported 
ORs and 95% CIs for each 1-mm Hg increment in SBPV.14 
Using the mean SBPV for the study populations, we con-
verted all ORs to ORs for the effect per 10-mm Hg increment 
in SBPV. The analysis showed nonsignificant heterogeneity 
between trials; so, we used a fixed effects model. SBPV was 
significantly associated with poor functional outcome: pooled 
OR, 1.2; CI (1.1–1.3); P
sig=0.0004; Phet=0.1 (Figure). Pooled 
OR estimates were similar for the same meta-analysis using 
random effects models, although they did not meet statistical 
significance (Table VII in the online-only Data Supplement). 
For the analysis including the study with the extreme result 
(Delgado-Mederos et al15), pooled OR estimates were similar 
and remained significant for the fixed effects model, although 
they did not meet statistical significance for the random 
effects model: fixed effect model pooled OR 1.2, CI (1.1–1.3), 
P
sig=0.0004, Phet=0.01; random effects model pooled OR 1.2, 
CI (0.9–1.5), P
sig=0.15.
On descriptive review of all studies that investigated asso-
ciations between SBPV and longer-term (≥3 months) func-
tional outcome after acute ischemic stroke, results are partly 
conflicting. Although some studies reported significant rela-
tionships between greater SBPV and poor outcomes15,20–22,28,29 
and significantly greater SBPV indices in poor outcome 
groups,13,22 others did not.16–18,24,27,30 Five retrospective obser-
vational analyses of large datasets reported SBPV to indepen-
dently predict functional outcome in acute ischemic stroke: 
Kang et al22 reported that systolic variability parameters 
were significantly associated with poor functional outcome 
in 2271 patients; Sare et al28 reported a significant relation-
ship between greater CV SBP and poor outcome in a post hoc 
analysis of 1722 patients; Endo et al20 reported a significant 
relationship between all included SBPV parameters (SD, 
CV, and SV) and death at 90 days, and a nonsignificant trend 
toward improved functional outcome with lower SBPV indi-
ces, in an analysis of stroke registry data. A post hoc analysis 
of data from the European Cooperative Acute Stroke Study 2 
(ECASS2) reported significant inverse associations between 
SV SBP and favorable 90-day functional outcome in tissue-
type plasminogen activator and placebo-treated groups.29 
Kellert et al21 reported a significant relationship between lower 
SBPV (SV SBP only) and favorable functional outcome in 
427 patients receiving thrombolytic therapy. In contrast to the 
findings reported in the above studies, a post hoc analysis of 
592 patients from the ECASS collaboration, using SV SBP as 
the sole variability parameter, revealed no significant relation-
ship between SBPV and functional outcome.30
In smaller study cohorts in acute ischemic stroke, sig-
nificant relationships with functional outcome were reported 
less frequently or were found in subgroups only: Tomii et al18 
reported no significant associations between SBPV (CV SBP 
only) and functional outcome in a prospective study of 130 
patients; Stead et al24 reported no association between SBPV 
and death at 90 days; Delgado-Mederos et al15 found a sig-
nificant relationship between SD SBP and outcome only in 
the subgroup of patients with persistent middle cerebral artery 
occlusion and in 80 patients thrombolyzed for ischemic stroke. 
Buratti et al13 found significantly higher SD SBP and CV SBP 
in those with poor functional outcome in a prospective cohort 
of patients with ischemic stroke and ipsilateral internal carotid 
artery occlusion. Graff et al16 found no differences in SBPV or 
diastolic BPV (DBPV) derived from beat-to-beat monitoring 
in 75 patients with ischemic stroke. In the one included study 
that used ambulatory BP monitoring (during 24 hours), no 
significant associations were found between SBP variability 
(defined as CV) and functional outcome.17
Two studies assessed the effect of BPV on 90-day func-
tional outcome in patients with acute ICH and elevated BP. 
Manning et al26 reported significant associations between SD 
SBP in the hyperacute phase (first 24 hours) and poor functional 
outcome and between SD SBP in the acute phase (day 2 to day 
7) and outcome. Furthermore, in sensitivity analyses, all SBPV 
parameters (SD, CV, residual SD, average real variability, and 
maximum SBP) were significantly associated with outcome. 
More recently, Tanaka et al19 reported a significant association 
between SV SBP during 24 hours and poor functional outcome 
in a prospective cohort of 205 patients with ICH, although they 
found no significant association with SD SBP.19
Three studies investigated the effects of BPV on functional 
outcomes (death alone, disability alone, or death and disabil-
ity combined) early after stroke (≤30 days).14,25,27 Although 1 
study found SD SBP to be an independent predictor of death 
and neurological deterioration at 10 days,25 the other 2 stud-
ies found no association between SBPV and outcome at ≤1 
month.14,27 Of 4 studies investigating the effect of BPV on neu-
rological deterioration <7 days of ischemic stroke onset, none 
reported significant associations with outcome.15,16,19,28
Heterogeneity in BPV parameters, outcome definitions, 
and reporting of results precluded a formal meta-analysis for 
the effect on neuroimaging outcomes, although certain non-
statistically significant trends were apparent (detailed in Table 
VIII in the online-only Data Supplement). One study found 
SD SBP to be an independent predictor of ischemic lesion 
growth on repeat magnetic resonance imaging scan in patients 
with acute ischemic stroke and persistent middle cerebral 
artery occlusion post thrombolysis but found no such asso-
ciation in those with middle cerebral artery recanalization.15 
Five studies investigated the effect of BPV on hemorrhagic 
complications (on repeat brain imaging) after ischemic stroke 
in patients eligible for thrombolysis.18,20–22,28 In studies where 
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100% of participants received thrombolytic therapy, 3 (of 4) 
reported significant associations between greater SBPV and 
hemorrhage on repeat brain imaging.18,20,21 A further 2 stud-
ies, recruiting those with ischemic stroke (in which 51% and 
64% received thrombolytic therapy), reported positive asso-
ciations between at least 1 reported SBPV parameter and 
hemorrhagic transformation on repeat imaging (Table VIII in 
the online-only Data Supplement).23,29 In acute ICH, neither of 
the 2 included articles found significant associations between 
SBPV and hematoma growth on repeat imaging.19,26
Although the primary focus of this review was on SBPV, 
DBPV was also considered (Tables VI and IX in the online-
only Data Supplement). The effects of DBPV indices on out-
come were considered in 16 studies, SD DBP being the most 
frequently used parameter.13–15,17–28,30 Reporting of results 
was often incomplete, and therefore, it precluded meta-anal-
yses. DBPV parameters were significantly associated with 
outcome in 8 studies: 4 reported associations with radiologi-
cal outcome,15,20,21,23 2 with death,20,24 4 with poor longer-term 
functional outcome,15,22,26,30 and 1 with poor functional out-
come at 30 days.14 The associations were often of border-
line significance or for some but not all parameters. DBPV 
was not significantly associated with radiological or short-
term functional or neurological outcomes in any included 
study.19–21,25,28,29 In acute ICH, 1 study reported mean arterial 
pressure and DBPV parameters to be weak but significant 
predictors of outcome,26 although another found no associa-
tion between DBPV and outcome.19
Discussion
This is the first systematic review to investigate the prognos-
tic significance of BPV in acute stroke and to bring together 
the current evidence about the measurement and definition of 
BPV in the acute-stroke setting. Pooled estimates for the effect 
of BPV suggest that greater SD SBP and CV SBP early after 
acute stroke may be associated with an increased risk of death 
and disability. Although these results must be interpreted with 
caution, nonstatistically significant trends described in our 
qualitative review support this finding, and in addition, they 
suggest that SBPV, measured early after acute stroke, is often 
associated with the risk of ICH in those treated with throm-
bolytic therapy. Conversely, SBPV does not seem to be asso-
ciated with short-term functional or neurological outcomes 
in acute ischemic stroke, and the prognostic significance of 
DBPV is uncertain.
Most studies (9 of 12), reporting the effect of BPV on lon-
ger-term functional outcome, found SBPV to be independently 
associated with death or dependency.15,19–22,26–29 Studies report-
ing such associations were more often those with higher num-
bers of patients (n>500), although those reporting neutral or 
nonsignificant results had smaller sample sizes (n<150)14,17,18,24 
and recruited a population with a noticeably lower average 
stroke severity.17,27 These findings are not based on quantita-
tive analysis and are merely hypothesis generating. Publication 
bias may have played a role in the former observation, with 
larger studies reporting positive results more likely to be pub-
lished. We aimed to minimize the risk of this as much as pos-
sible through our exhaustive approach to the literature review.
Interestingly, most studies in which BP measurements 
commenced early from stroke onset15,19–21,26,28,29 reported posi-
tive associations between SBPV and poor longer-term func-
tional outcomes or hemorrhagic complications on repeat 
brain imaging, whereas studies in which BP measurements 
commenced later (>12 hours from stroke onset) more often 
reported no, or weaker, associations with outcome.14,16,17,23,24,27 
All studies that assessed the relationship between SBPV and 
risk of intracranial hemorrhage post thrombolysis for acute 
ischemic stroke reported significant associations, with greater 
SBPV being associated with increased risk.18,20,21,23,30 In acute 
ICH, both included studies found associations between SBPV 
and functional outcome but not hematoma growth.19,26 We 
found limited and conflicting data on associations between 
DBPV and functional, neurological, or radiological outcomes, 
and because of a combination of heterogeneity and incom-
plete reporting of results cannot draw firm conclusions as to 
its potential prognostic significance.
The findings of this review must be interpreted with cau-
tion. In particular, reverse causality, whereby larger strokes, 
with a poorer prognosis may give rise to greater variability 
in BP, cannot be excluded. However, there are other plausible 
hypotheses to explain the observed relationship between BPV 
and outcomes, most of which relate to the effects of BP fluc-
tuations, on an increasingly pressure-dependant cerebral cir-
culation. Cerebral autoregulation is impaired in acute stroke,31 
and dynamic BP fluctuations, in the context of greater BPV, 
may lead to increased cerebral edema, or risk of hemorrhagic 
transformation, in this pressure-dependent cerebral circula-
tion. Indeed in those receiving thrombolytic therapy, greater 
fluctuations or sudden BP increases may exacerbate the del-
eterious effects of reperfusion injury on salvageable ischemic 
tissue, which may in part explain the reported associations 
between greater BPV and poor outcome in studies of this 
patient group.
The pathophysiological effects of greater BPV on brain 
tissue may vary depending on the degree of impairment in 
cerebral autoregulation, which is influenced by factors such as 
infarct size.32,33 Thus, in those with more severe strokes with 
greater cerebral dysautoregulation, BPV may exert greater 
pathophysiological effects than in those with milder dis-
ease. Another hypothesis relates to the potential difference in 
pathophysiological effects of BPV on potentially viable brain 
tissue (the ischemic penumbra) versus effects on the irrevers-
ibly damaged ischemic core and may help explain why stud-
ies commencing BP measurements earlier more often found 
associations with outcome. Perhaps in the first few hours after 
onset, the potentially salvageable penumbral tissue is particu-
larly vulnerable to the effects of BP fluctuations, with sudden 
BP declines increasing the risk of further ischemia and reduc-
ing the chances of reperfusion, and abrupt BP rises increasing 
the risk of hemorrhage.
Greater SBP fluctuations may contribute to ongoing bleed-
ing and hematoma growth in ICH, and hypotensive episodes 
associated with greater BPV may lead to secondary cerebral 
ischemia or enhance the formation of cerebral edema. Indeed, 
a significant correlation between BP instability (and barore-
ceptor sensitivity) and relative edema after ICH was reported 
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Table.  Study Characteristics
Study Patient Numbers Study Design Stroke Type*
Thrombolytic  
Therapy Given?†
Average Initial  
Stroke Severity‡§
Antihypertensives 
Given?
Time From Stroke 
Onset to Recruitment
BP Measurement Technique and Duration of 
Monitoring
No. of BP Measures 
From Which BPV 
Calculated
BPV Parameters 
Included in Analyses Outcome Measures
Buratti et al,13 2014 89 Prospective observational analysis AIS No Good outcome 8;  
poor outcome 9.5
Yes, as per normal 
clinical practice
≤9 h Casual cuff BP for 48 h ≥10 SD, CV Functional outcome
Dawson et al,14 2000 92 Prospective observational analysis AIS No Not reported No <72 h Beat-to-beat BP for 10 min Beat-to-beat SD Functional outcome
Delgado-Mederos et al,15 2008 80 Prospective observational analysis AIS Yes (100%) 15 (10–19) Yes, as per normal 
clinical practice
<6 h Casual cuff BP for 24 h 52 SD Functional outcome, 
END, infarct volume 
on MRI
Endo et al,20 2013 527 Observational analysis (stroke registry) AIS Yes (100%) 12 (7–18) Yes, as per normal 
clinical practice
<6 h Casual cuff BP for 24 h 6 SD, SV, CV Functional outcome, 
ICH*
Geeganage et al,25 2011 1479 Observational analysis (RCT data) AIS No Not stated Not stated <48 h Casual cuff BP (duration unknown) Not stated SD Functional outcome, 
END
Graff et al,16 2013 75 Prospective observational analysis AIS Not stated 5 Yes, as per normal 
clinical practice
<7 d (median, 2 d) Beat-to-beat BP (duration unknown) Beat-to-beat SD Functional outcome, 
END
Kang et al,22 2012 2271 Observational analysis (stroke registry) AIS Yes (12.9%) 3 (2–7) Yes, as per normal 
clinical practice
72 h Casual cuff BP for median duration 8.7 days 
(IQR, 6.8–11.9) from stroke onset; BPV 
calculated from 72 h post stroke to hospital 
discharge
Median 34 SD, CV Functional outcome
Kellert et al,21 2012 427 Observational analysis (stroke registry) AIS Yes (all) ICH negative 10.5 (9), ICH positive 
14 (8) (quoted as mean [SD])
Yes, as per normal 
clinical practice
<6 h Casual cuff BP for 24 to 36 h (no median 
quoted)
Median 21.5 (IQR, 9.5) SV Functional outcome, 
ICH*
Ko et al,23 2010 792 Observational analysis (stroke registry) AIS Yes (64.3%) HT negative 4 (2–8);  
HT positive 13 (7–18)
Yes, as per normal 
clinical practice
<24 h Casual cuff BP for 72 h Median 18 (IQR, 14–57) SD, SV, maximum SV ICH║
Manning et al,26 2014 2645 Observational analysis (RCT data) ICH No 10 (6–15) Yes, trial protocol < 6 h Casual cuff BP for the first 24 h and from day 
2 to day 7
5 in day 1, 12 from day 
2 to day 7
SD, CV, VIM, ARV, RSD Functional outcome, 
hematoma growth*
Manning et al,27 2015 934 Observational analysis (RCT data) ICH and AIS No COSSACS: 4 (3–8);  
CHHIPS 9 (5–16)
Yes, trial protocol <48 h Casual cuff BP for 10 min 6 SD, CV, ARV, VIM Functional outcome
Sare et al,28 2009 1722 Observational analysis (RCT data) AIS No 11 (8–17) Yes, dependant on trial <6 h Casual cuff BP for 24 h 7 CV Functional outcome, 
END
Stead et al,24 2006 71 Observational analysis (stroke registry) AIS Not stated 11.8 (10.4) (quoted  
as mean [SD])
No <24 h Casual cuff BP for 3 h Median 9 (range, 2–30) Slope (fitting linear 
regression to curve), 
% change from 
baseline SBP
Death
Tanaka et al,19 2014 205 Prospective observational analysis ICH No 13 (8–17) Yes, IV Nicardipine as 
per study protocol
<3 h Casual cuff BP for 24 h 24 SD, SV Functional outcome
Tomii et al,17 2011 (24-h BP) 104 Prospective observational analysis AIS Yes (15%) 4 (1–8) Yes, as per normal 
clinical practice
<24 h ABPM for 24 h on day 2 and day 7 post stroke 48 in each 24-h period CV Functional outcome
Tomii et al,18 2011 125 Prospective observational analysis AIS Yes (100%) 13 (7–18) Yes, as per normal 
clinical practice
<3 h Casual cuff for 24 h 28 CV Functional outcome, 
ICH*
Yong et al,25 2005 791 Observational analysis (RCT data) AIS Yes (50.4%) SSS categorized into groups:  
0–14, 12.3%; 15–25, 26.5%; 
26–35, 32.03%; >36, 26.17%
Not stated <6 h Casual cuff for 24 h 37 SV Functional outcome,
Yong et al,29 2008 592 Observational analysis of RCT data AIS Yes (51.3%) SSS by SBP group (mean SD): 
SBP≤140, 27.4 (11.1);  
SBP≥140, 31.5 (11.3)
Not stated <6 h Casual cuff for 72 h 23 SV Functional outcome, 
ICH*
Functional outcome: measured on the modified Rankin scale or equivalent. Further information on timing and exact definitions of outcome measures can be found 
in Table V in the online-only Data Supplement. ABPM indicates ambulatory blood pressure monitoring; AIS, acute ischemic stroke; ARV, average real variability; BP, 
blood pressure; BPV, blood pressure variability; CHHIPS, Controlling Hypertension and Hypotension Immediately Post Stroke; COSSACS, Continue or Stop Post-Stroke 
Antihypertensives Collaborative Study; CV, coefficient of variation; END, early neurological deterioration; HT, hemorrhagic transformation of infarct on brain imaging; 
ICH, intracerebral hemorrhage; IQR, interquartile range; MAP, mean arterial pressure; MRI, magnetic resonance imaging; NIHSS, National Institute of Health Stroke 
Scale; PP, pulse pressure; RCT, randomized controlled trial; RSD, residual standard deviation; SBP, systolic blood pressure; SSS, Scandinavian Stroke Scale; SV, 
successive variation; and VIM, variation independent of the mean.
*Stroke type described as ischemic only/ICH only/both ischemic and ICH included.
†Where thombolytic therapy given, % of participants receiving therapy given in brackets.
‡Given for the whole cohort, unless reported by outcome group only in the original article, in which case, reported by outcome group.
§NIHSS given unless otherwise stated. Quoted as median (IQR where reported) unless otherwise stated.
║Identified on repeat brain imaging.
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Table.  Study Characteristics
Study Patient Numbers Study Design Stroke Type*
Thrombolytic  
Therapy Given?†
Average Initial  
Stroke Severity‡§
Antihypertensives 
Given?
Time From Stroke 
Onset to Recruitment
BP Measurement Technique and Duration of 
Monitoring
No. of BP Measures 
From Which BPV 
Calculated
BPV Parameters 
Included in Analyses Outcome Measures
Buratti et al,13 2014 89 Prospective observational analysis AIS No Good outcome 8;  
poor outcome 9.5
Yes, as per normal 
clinical practice
≤9 h Casual cuff BP for 48 h ≥10 SD, CV Functional outcome
Dawson et al,14 2000 92 Prospective observational analysis AIS No Not reported No <72 h Beat-to-beat BP for 10 min Beat-to-beat SD Functional outcome
Delgado-Mederos et al,15 2008 80 Prospective observational analysis AIS Yes (100%) 15 (10–19) Yes, as per normal 
clinical practice
<6 h Casual cuff BP for 24 h 52 SD Functional outcome, 
END, infarct volume 
on MRI
Endo et al,20 2013 527 Observational analysis (stroke registry) AIS Yes (100%) 12 (7–18) Yes, as per normal 
clinical practice
<6 h Casual cuff BP for 24 h 6 SD, SV, CV Functional outcome, 
ICH*
Geeganage et al,25 2011 1479 Observational analysis (RCT data) AIS No Not stated Not stated <48 h Casual cuff BP (duration unknown) Not stated SD Functional outcome, 
END
Graff et al,16 2013 75 Prospective observational analysis AIS Not stated 5 Yes, as per normal 
clinical practice
<7 d (median, 2 d) Beat-to-beat BP (duration unknown) Beat-to-beat SD Functional outcome, 
END
Kang et al,22 2012 2271 Observational analysis (stroke registry) AIS Yes (12.9%) 3 (2–7) Yes, as per normal 
clinical practice
72 h Casual cuff BP for median duration 8.7 days 
(IQR, 6.8–11.9) from stroke onset; BPV 
calculated from 72 h post stroke to hospital 
discharge
Median 34 SD, CV Functional outcome
Kellert et al,21 2012 427 Observational analysis (stroke registry) AIS Yes (all) ICH negative 10.5 (9), ICH positive 
14 (8) (quoted as mean [SD])
Yes, as per normal 
clinical practice
<6 h Casual cuff BP for 24 to 36 h (no median 
quoted)
Median 21.5 (IQR, 9.5) SV Functional outcome, 
ICH*
Ko et al,23 2010 792 Observational analysis (stroke registry) AIS Yes (64.3%) HT negative 4 (2–8);  
HT positive 13 (7–18)
Yes, as per normal 
clinical practice
<24 h Casual cuff BP for 72 h Median 18 (IQR, 14–57) SD, SV, maximum SV ICH║
Manning et al,26 2014 2645 Observational analysis (RCT data) ICH No 10 (6–15) Yes, trial protocol < 6 h Casual cuff BP for the first 24 h and from day 
2 to day 7
5 in day 1, 12 from day 
2 to day 7
SD, CV, VIM, ARV, RSD Functional outcome, 
hematoma growth*
Manning et al,27 2015 934 Observational analysis (RCT data) ICH and AIS No COSSACS: 4 (3–8);  
CHHIPS 9 (5–16)
Yes, trial protocol <48 h Casual cuff BP for 10 min 6 SD, CV, ARV, VIM Functional outcome
Sare et al,28 2009 1722 Observational analysis (RCT data) AIS No 11 (8–17) Yes, dependant on trial <6 h Casual cuff BP for 24 h 7 CV Functional outcome, 
END
Stead et al,24 2006 71 Observational analysis (stroke registry) AIS Not stated 11.8 (10.4) (quoted  
as mean [SD])
No <24 h Casual cuff BP for 3 h Median 9 (range, 2–30) Slope (fitting linear 
regression to curve), 
% change from 
baseline SBP
Death
Tanaka et al,19 2014 205 Prospective observational analysis ICH No 13 (8–17) Yes, IV Nicardipine as 
per study protocol
<3 h Casual cuff BP for 24 h 24 SD, SV Functional outcome
Tomii et al,17 2011 (24-h BP) 104 Prospective observational analysis AIS Yes (15%) 4 (1–8) Yes, as per normal 
clinical practice
<24 h ABPM for 24 h on day 2 and day 7 post stroke 48 in each 24-h period CV Functional outcome
Tomii et al,18 2011 125 Prospective observational analysis AIS Yes (100%) 13 (7–18) Yes, as per normal 
clinical practice
<3 h Casual cuff for 24 h 28 CV Functional outcome, 
ICH*
Yong et al,25 2005 791 Observational analysis (RCT data) AIS Yes (50.4%) SSS categorized into groups:  
0–14, 12.3%; 15–25, 26.5%; 
26–35, 32.03%; >36, 26.17%
Not stated <6 h Casual cuff for 24 h 37 SV Functional outcome,
Yong et al,29 2008 592 Observational analysis of RCT data AIS Yes (51.3%) SSS by SBP group (mean SD): 
SBP≤140, 27.4 (11.1);  
SBP≥140, 31.5 (11.3)
Not stated <6 h Casual cuff for 72 h 23 SV Functional outcome, 
ICH*
Functional outcome: measured on the modified Rankin scale or equivalent. Further information on timing and exact definitions of outcome measures can be found 
in Table V in the online-only Data Supplement. ABPM indicates ambulatory blood pressure monitoring; AIS, acute ischemic stroke; ARV, average real variability; BP, 
blood pressure; BPV, blood pressure variability; CHHIPS, Controlling Hypertension and Hypotension Immediately Post Stroke; COSSACS, Continue or Stop Post-Stroke 
Antihypertensives Collaborative Study; CV, coefficient of variation; END, early neurological deterioration; HT, hemorrhagic transformation of infarct on brain imaging; 
ICH, intracerebral hemorrhage; IQR, interquartile range; MAP, mean arterial pressure; MRI, magnetic resonance imaging; NIHSS, National Institute of Health Stroke 
Scale; PP, pulse pressure; RCT, randomized controlled trial; RSD, residual standard deviation; SBP, systolic blood pressure; SSS, Scandinavian Stroke Scale; SV, 
successive variation; and VIM, variation independent of the mean.
*Stroke type described as ischemic only/ICH only/both ischemic and ICH included.
†Where thombolytic therapy given, % of participants receiving therapy given in brackets.
‡Given for the whole cohort, unless reported by outcome group only in the original article, in which case, reported by outcome group.
§NIHSS given unless otherwise stated. Quoted as median (IQR where reported) unless otherwise stated.
║Identified on repeat brain imaging.
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in a recent observational study.34 All of the above hypotheses 
remain speculative at present, given the lack of prospective 
studies investigating the effect of BPV on the blood supply to 
the ischemic penumbra and surrounding tissue in acute stroke.
The pathophysiological mechanisms responsible for 
the observed associations between BPV and longer- but not 
shorter-term functional or neurological outcomes remain 
unclear, and given the lack of available data on the natural 
history of BPV after stroke, it is difficult to suggest robust 
hypotheses. Perhaps BPV in the acute stroke period correlates 
with BPV several weeks or months from the event, in which 
case, the effects of BPV on large and small artery remodeling 
and associated changes in arterial function may be relevant.35 
These uncertainties should be addressed in future prospective 
studies, which in the first instance should determine the course 
of BPV in the short and longer term after stroke.
There is currently no consensus as to the best parameter 
to use to estimate BPV in acute stroke. A variety of param-
eters were used to define BPV across the studies in this review. 
Only 1 study performed discriminatory analyses to determine 
the most useful outcome predictors.26 In most studies using >1 
variability parameter, either all included SBP parameters were 
associated with outcome or no associations were found. No 
one parameter was consistently associated with outcome and 
another, consistently not. Furthermore, no study used >1 BP 
measurement technique in the same cohort of patients; so, no 
direct comparisons between techniques can be made in terms 
of ability to capture BP variations or acceptability to partici-
pants. Therefore, we cannot comment on the most useful BPV 
parameter, or the most appropriate BP measurement technique 
for the purposes of BPV estimation in acute stroke.
This study has several limitations. Our meta-analysis 
was limited to only 7 studies because of the heterogeneity in 
methodology and reporting of results, thus, limiting the statis-
tical power and precision of results. Furthermore, the analyses 
were based on adjusted ORs from each trial rather than on 
more sensitive actuarial analysis of individual patient data. 
BPV increases proportionally to mean BP in hypertensive 
individuals, and some studies did not adjust for BP level in 
their analyses; of studies included in the meta-analysis, 4 stud-
ies adjusted for mean SBP18,22,26,27; and 1 study did not adjust 
the reported OR but reported no heterogeneity in the effect 
of BPV on outcome across groups depending on mean BP 
level.14 The relationship between the BP level and outcome 
after stroke is complex and nonlinear; adjustment for BP level 
between studies was heterogeneous; and thus, any attempt to 
adjust for this in the meta-analysis would be complicated and 
may even cause artifact. The meta-analysis included studies 
of both acute ICH and acute ischemic stroke combined. As BP 
management strategies, target BP level, and evidence for the 
effect on BP lowering on outcome is different in acute isch-
emic stroke compared with ICH, our results may not reflect 
the relationship between BPV and the stroke subtypes when 
considered as 2 separate entities. However, we are limited by 
the small number of studies eligible for inclusion in the analy-
sis, with only 1 study recruiting patients with acute ICH only 
and 1 enrolling a cohort including both stroke subtypes but 
predominantly ischemic stroke. Most of the larger included 
studies were post hoc analyses and thus, prone to selection 
bias. Furthermore, reverse causality cannot be excluded, as 
discussed previously. Finally, many studies included patients 
receiving antihypertensive therapy, although few described 
drugs, or doses used, or reported on the potential effect of such 
drugs on BPV and outcome.
A main finding of this review was heterogeneity in cur-
rently available data. In future studies, to create a homogenous 
Dawson 2000 2.0 0.3-6.2
Endo 2013 1.4 0.8-2.1
Tomii 2011* (24 hour) 0.4 0.1-1.8
Tomii 2011* (casual) 1.3 0.3-6.3
Kang 2012 1.7 1.2-2.2
Manning 2014 1.2 1.1-1.4
Manning 2015 (COSSACS) 1.0 0.5-1.7
Manning 2015 (CHHIPS) 0.9 0.8-1.3
TOTAL 1.2 1.1-1.3
Significance: p = 0.0004
Heterogeneity: p = 0.10
OR 95% CI
0 1 2 3 4 5 6
Odds Ratio (95% CI)
Figure. Forrest plot of the association between systolic blood pressure variability (SBPV) and poor functional outcome (death or disabil-
ity). Included studies quoted odds ratio (OR) for the effect of SD SBP on outcome unless otherwise indicated. OR quoted for the effect 
per 10-mm Hg increment in SBPV. *Reported OR (95% confidence interval [CI]) for the effect per 10-mm Hg coefficient of variation (CV) 
SBP, where CV=(SD/mean)×100 mm Hg.17,18 ORs are likely to be overestimates compared with those studies quoting OR per 10-mm Hg 
increment in SD SBP. †Separate ORs provided for Hypertension and Hypotension Immediately Post Stroke (CHHIPS) and Continue or 
Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS) cohorts in the original article27; therefore, 2 ORs also used for the 
purposes of meta-analysis.
Manning et al  BPV in Acute Stroke: A Systematic Review   2489
set of data amenable to meta-analysis and to find from which 
robust conclusions can be drawn about the most appropriate 
definition and measurement of BPV, and its effects on out-
come after acute stroke, we would recommend the following 
as a minimum: authors should provide a detailed description 
of the study population, in particular, the number and class 
of preexisting antihypertensive medications; the timing and 
duration of BP measurements should be clearly stated, as 
should the time from stroke onset and the time from which 
outcome events were included; analyses should include at 
least 2 BPV parameters and should include SD or CV; mean 
SD for the population should be stated; BPV should be mea-
sured during the short (minutes) and longer terms (hours to 
days); a description of the relationship between BP level 
and outcome should be provided, and authors should state if 
and how any adjustment for BP level was performed in their 
analyses; authors should report the effect of both SBPV and 
DBPV; investigators should use a range of BP measurement 
techniques to capture BPV; acceptability and failure rates of 
BP measurement devices should be assessed.
Nonetheless, this review brings together the current evi-
dence about the potential prognostic significance of BPV in 
acute stroke, and although we cannot make recommendations 
for clinical practice based on our findings, the present review 
will inform future research. Given the variable efficacies of 
different antihypertensive agents on stroke risk reduction that 
cannot be explained purely by effects on mean BP reduction 
alone (with calcium-channel blockers being most protective)9
 
and the highly consistent and significant drug class effects 
on interindividual BPV,9,10 where calcium-channel blockers 
and nonloop diuretics reduce variation although angiotensin 
receptor and β-blockers increase it, BPV may represent a 
modifiable therapeutic target in acute stroke. Future research 
aimed at determining the feasibility and effect of reducing 
BPV in acute stroke is justified, although first, prospective 
studies of the minimum standard described above should aim 
to address how best to measure and define BPV.
Conclusions
This systematic review and meta-analysis suggest that greater 
SBPV, measured early from ischemic stroke or ICH onset, 
is associated with poor longer-term functional outcome. 
In addition, in those with acute ischemic stroke eligible for 
thrombolytic therapy, increased BPV is frequently associated 
with increased risk of hemorrhage on repeat brain imaging. 
Although robust conclusions cannot be drawn because of 
limitations in the quality of included studies and heterogene-
ity in study methodology, this is the first review to investigate 
the prognostic significance of BPV in acute stroke, and our 
results will inform future studies. In addition, our results have 
potential implications for clinical practice, whereby clinicians 
should aim for smooth and sustained control of BP in acute 
stroke and not solely focus on absolute or average BP values.
A paucity of data directly comparing the predictive 
value of different BPV parameters, the timing and duration 
of BPV measurements, and the practicality and acceptability 
to patients of the various BP measurement techniques, in the 
acute stroke population, means that we cannot firmly conclude 
how best to measure or define BPV. Further prospective work 
is needed before embarking on larger studies to determine the 
feasibility and efficacy of reducing BPV after acute stroke and 
to assess its effect on outcome.
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